Search

Your search keyword '"Kohtamäki, Laura"' showing total 15 results
Start Over Author "Kohtamäki, Laura"
15 results on '"Kohtamäki, Laura"'

4. Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor

Author

Mattila, Kalle E., primary, Mäkelä, Siru, additional, Kytölä, Soili, additional, Andersson, Emma, additional, Vihinen, Pia, additional, Ramadan, Susan, additional, Skyttä, Tanja, additional, Tiainen, Leena, additional, Vuoristo, Meri-Sisko, additional, Tyynelä-Korhonen, Kristiina, additional, Koivunen, Jussi, additional, Kohtamäki, Laura, additional, Aittomäki, Kristiina, additional, and Hernberg, Micaela, additional

Published
2022
Full Text
View/download PDF

5. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Author

Kohtamäki, Laura, primary, Arjama, Mariliina, additional, Mäkelä, Siru, additional, Ianevski, Philipp, additional, Välimäki, Katja, additional, Juteau, Susanna, additional, Ilmonen, Suvi, additional, Ungureanu, Daniela, additional, Kallioniemi, Olli, additional, Murumägi, Astrid, additional, and Hernberg, Micaela, additional

Published
2022
Full Text
View/download PDF

6. Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs

Author

Tulokas, Sanni K. A., primary, Kohtamäki, Laura M., additional, Mäkelä, Siru P., additional, Juteau, Susanna, additional, Albäck, Anders, additional, Vikatmaa, Pirkka J., additional, Mattila, Kalle E., additional, Skyttä, Tanja K., additional, Koivunen, Jussi P., additional, Tyynelä-Korhonen, Kristiina, additional, and Hernberg, Micaela M., additional

Published
2021
Full Text
View/download PDF

7. Ihomelanooman onkologinen hoito päivittyi

Author

Mattila, Kalle, Vihinen, Pia, Skyttä, Tanja, Tiainen, Leena, Vuoristo, Meri-Sisko, Kettunen, Tiia, Tyynelä-Korhonen, Kristiina, Iivanainen, Sanna, Kohtamäki, Laura, Mäkelä, Siru, Hernberg, Micaela, Tampere University, Syövänhoidon vastuualue, and Kliininen lääketiede

Subjects
3122 Syöpätaudit
Abstract

publishedVersion

Published
2021

10. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Author

Mattila, Kalle E., primary, Vihinen, Pia, additional, Ramadan, Susan, additional, Skyttä, Tanja, additional, Tiainen, Leena, additional, Vuoristo, Meri-Sisko, additional, Tyynelä-Korhonen, Kristiina, additional, Koivunen, Jussi, additional, Kohtamäki, Laura, additional, Mäkelä, Siru, additional, and Hernberg, Micaela, additional

Published
2019
Full Text
View/download PDF

12. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.

Author

Mattila, Kalle E., Vihinen, Pia, Ramadan, Susan, Skyttä, Tanja, Tiainen, Leena, Vuoristo, Meri-Sisko, Tyynelä-Korhonen, Kristiina, Koivunen, Jussi, Kohtamäki, Laura, Mäkelä, Siru, and Hernberg, Micaela

Subjects
ANTINEOPLASTIC agents, THERAPEUTIC use of interferons, CANCER chemotherapy, MELANOMA, TUMOR classification, VINCRISTINE, TREATMENT effectiveness, TEMOZOLOMIDE
Abstract

The article focuses on the combination chemotherapy and interferon-alpha (IFN) increased response rate to 50–60 percent but failed to prolong survival. It mentions that brain metastases are still associated with poor survival, although remarkably long intracranial responses have been observed with combination therapies; and also mentions the efficacy and safety of chemo immunotherapy with vemurafenib in advanced melanoma patients.

Published
2020
Full Text
View/download PDF

13. High-throughput ex vivodrug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Author

Kohtamäki, Laura, Arjama, Mariliina, Mäkelä, Siru, Ianevski, Philipp, Välimäki, Katja, Juteau, Susanna, Ilmonen, Suvi, Ungureanu, Daniela, Kallioniemi, Olli, Murumägi, Astrid, and Hernberg, Micaela

Abstract

•We established patient-derived cancer cell (PDC) lines from NRAS-positive MM tumors.•We carried out high-throughput drug testing with PDCs against 527 oncology drugs.•PDCs were sensitive to PI3K, mTOR, PLK1, MEK, ERK, and RAF inhibitors.•Drug combination synergies were identified.•Our results support application of PDCs for functional drug testing.

Published
2022
Full Text
View/download PDF

14. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Author

Mattila, Kalle E., Vihinen, Pia, Ramadan, Susan, Skyttä, Tanja, Tiainen, Leena, Meri-Sisko Vuoristo, Tyynelä-Korhonen, Kristiina, Koivunen, Jussi, Kohtamäki, Laura, Mäkelä, Siru, and Hernberg, Micaela

Subjects
organic chemicals, bacteria, 3. Good health
Abstract

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

15. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Author

Mattila, Kalle E., Vihinen, Pia, Ramadan, Susan, Skyttä, Tanja, Tiainen, Leena, Meri-Sisko Vuoristo, Tyynelä-Korhonen, Kristiina, Koivunen, Jussi, Kohtamäki, Laura, Mäkelä, Siru, and Hernberg, Micaela

Subjects
organic chemicals, bacteria, 3. Good health
Abstract

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Catalog

Books, media, physical & digital resources
See catalog results